MDS 2023 | Emerging levodopa-based treatment strategies for PD: SC delivery
Dag Nyholm, MD, PhD, Uppsala University, Uppsala, Sweden, discusses the exciting advancements in levodopa-based treatment strategies for Parkinson’s disease (PD) currently in development. Subcutaneous (SC) delivery of levodopa shows great potential, and the first therapy is expected to be marketed soon. Still, its effectiveness compared to current treatments such as intestinal or jejunal infusions remains unknown. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Prof. Nyholm has received grant support from EU Joint Programme – Neurodegenerative Disease Research (JPND), Swedish Brain Foundation, Swedish Parkinson’s Disease Foundation, Swedish Research Council, Vinnova (Sweden’s Innovation Agency); consultancy fees from Britannia, Medtronic, NeuroDerm, NordicInfu Care, Orion, Stada; lecture fees from AbbVie and Britannia; remuneration for participating in expert panels at the websites internetmedicin.se and netdoktor.se; and publishing royalties from Liber AB. He has participated as an investigator in clinical trials sponsored by Dizlin, GSK, Integrative Research Labs, Ipsen, Lobsor, Neurolixis, Sensidose, Solvay/Abbott/AbbVie.
